Navigation Links
NexMed Announces Completion of Patient Enrollment in Two Pivotal,Phase 3 Studies for Anti-Fungal Product

EAST WINDSOR, N.J.--(BUSINESS WIRE)--July 9, 2007 - NexMed, Inc. (NASDAQ: NEXM), a developer of innovative transdermal treatments based on the NexACT(R) drug delivery technology, today announced that Novartis Pharma AG has completed patient enrollment for Phase III clinical trials for NM100060, a topical treatment for onychomycosis (nail fungus). Pursuant to the terms of the licensing agreement with Novartis, NexMed will be entitled to a milestone payment early next year. NexMed entered into an exclusive, worldwide agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM10060.

NM100060 is a topical application of Lamisil(R) (terbinafine), formulated with terbinafine and the Company's patented NexACT permeation enhancer, which facilitates the delivery of the drug into the nail bed, where the fungus resides.

About NexMed

NexMed, Inc. is an emerging drug developer that is leveraging its proprietary drug technology to develop a significant pipeline of innovative pharmaceutical products to address significant unmet medical needs. The Company is also working with various pharmaceutical companies to explore the incorporation of NexACT(R) into their existing drugs as a means of developing new patient-friendly transdermal products and extending patent lifespans and brand equity. For further information about the Company, go to www.nexmed.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to its ability to maintain reduced expenditures, enter into partnering agreements, pursue growth opportunities, and/or other factors, some of which are outside the control of the Company.

Contact

NexMed, Inc.
Linda Burns, 609-371-8123, ext: 184
Senior Director Corporate Relations
lburns@nexmed.com
or
Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/27/2020)... ... 2020 , ... Respected dentists, Drs. Kenneth and Jonathan Nash ... Santo Domingo, Dominican Republic. The dentists performed advanced dental procedures on underprivileged patients ... surgery for dental implants to replace missing teeth in Vicksburg, MS, ...
(Date:1/27/2020)... Calif. (PRWEB) , ... January 27, 2020 , ... A ... Xiaofeng, a 15-year-old girl living in China’s Liaoning province afflicted with a rare disease ... had the appearance of a woman in her sixties or older. With the help ...
(Date:1/27/2020)... ... January 27, 2020 , ... ... Qigong Grand Master, founder of Global Healing Alliance, Bay Area , https://www.voiceamerica.com/episode/121202/dare-to-dream-and-live-it ... September 28th, the same day as Confucious, travels the world teaching the gentle ...
Breaking Medicine Technology:
(Date:1/24/2020)... ... January 24, 2020 , ... Devcool Inc ( http://www.devcool.com ... it has completed its spin-off of HiPaaS, Inc ( http://www.hipaas.com ). HiPaaS ... Inc continues its growth and focuses on Healthcare consulting services. , With ...
(Date:1/23/2020)... ... January 23, 2020 , ... The Icahn School of ... and patient care—today announced the recipients of the first-of-its-kind Distinguished Scholar Award, a ... Medicine. The awards aim to mitigate gender gaps in medical research by supporting ...
(Date:1/23/2020)... Okla (PRWEB) , ... January 23, 2020 , ... ... partnered with RespirCare, LLC, a first-of-its-kind, full-service pulmonology clinic based in Tulsa, to ... Under the agreement, MCNDOH patients will also have access to HGE Health’s digital ...
(Date:1/23/2020)... ... 23, 2020 , ... Three leading healthcare organizations, Advocate Aurora ... diagnostic quality and safety by joining the Coalition to Improve Diagnosis , ... patient advocacy. , “Diagnostic error is one of the most important safety problems ...
(Date:1/23/2020)... Ga. (PRWEB) , ... January 23, 2020 , ... Dr. ... McCalla to become a new member of their professional dental staff. The ... including general dentistry, cosmetic dentistry, emergency dentistry and restorative dentistry, all in ...
Breaking Medicine News(10 mins):